Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > September 18, 2024
Daily News
September 18, 2024
- Enhertu Effective in HER2 Breast Cancer with Brain Metastases
September 18, 2024
- Daiichi Sankyo’s HER3 ADC Hits PFS Goal in EGFR-Mutant Lung Cancer
September 18, 2024
- Lenvima/Keytruda Added to TACE Extend PFS in HCC
September 18, 2024
- Kissei’s Fibroid Drug Linzagolix Hits German Market
September 18, 2024
- GSK’s Multiple Myeloma Drug Blenrep Filed in Japan
September 18, 2024
- Sandoz Now Distributor of FKB’s Humira Biosimilar in Japan
September 18, 2024
- MSD Files Belzutifan for von Hippel-Lindau Disease in Japan
September 18, 2024
- MHLW Working Group Gets into Details of Proposed Drug Supply Info System
September 18, 2024
- “Kobe Model” Offers Unique Subsidy to Diagnose Dementia, Test Eligibility for Lecanemab
September 18, 2024
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…